Unoprostone isopropyl formulation (Rescula, Sucampo) makes alternative mechanism available for lowering IOP in open-angle glaucoma or ocular hypertension.
Bethesda, MD-Sucampo Pharmaceuticals’ formulation of unoprostone isopropyl ophthalmic solution 0.15% (Rescula) is now available by prescription across the United States, according to the company.
The FDA approved a supplemental new drug application for the big-potassium channel activator on Dec. 7, 2012 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
According to the approved product labeling, the solution may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower IOP.
For more articles in this issue of Ophthalmology Times eReport, click here.